| Bioactivity | bPiDDB is a potent nAChR antagonist. bPiDDB potently (IC50=2 nM) inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs[1]. | ||||||||||||
| In Vivo | bPiDDB (外周给药) 可抑制伏隔核中尼古丁诱发的多巴胺 (DA) 释放，降低大鼠尼古丁的成瘾性[1]。bPiDDB 在外周给药后具有脑生物可利用性，并由血脑屏障胆碱转运体主动运输到中央室[1]。 | ||||||||||||
| Name | bPiDDB | ||||||||||||
| CAS | 525596-66-1 | ||||||||||||
| Formula | C24H38Br2N2 | ||||||||||||
| Molar Mass | 514.38 | ||||||||||||
| Appearance | Oil | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Smith AM, et al. Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochem Pharmacol. 2010 Aug 1;80(3):402-9. |